HIGH TIDE INC (HITI.CA) Stock Fundamental Analysis
Canada - TSX-V:HITI - CA42981E4013 - Common Stock
3.69 CAD
-0.11 (-2.89%)
We assign a fundamental rating of 4 out of 10 to HITI. HITI was compared to 32 industry peers in the Pharmaceuticals industry. While HITI seems to be doing ok healthwise, there are quite some concerns on its profitability. HITI has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
HITI had negative earnings in the past year.
HITI had a positive operating cash flow in the past year.
HITI had negative earnings in each of the past 5 years.
Of the past 5 years HITI 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of HITI (-3.76%) is comparable to the rest of the industry.
HITI's Return On Equity of -6.93% is fine compared to the rest of the industry. HITI outperforms 62.50% of its industry peers.
With a decent Return On Invested Capital value of 4.61%, HITI is doing good in the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.76% | ||
| ROE | -6.93% | ||
| ROIC | 4.61% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HITI has a Operating Margin of 2.30%. This is in the better half of the industry: HITI outperforms 65.63% of its industry peers.
With a Gross Margin value of 25.83%, HITI is not doing good in the industry: 71.88% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of HITI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.3% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so HITI is destroying value.
The number of shares outstanding for HITI has been increased compared to 1 year ago.
Compared to 5 years ago, HITI has more shares outstanding
HITI has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.06 indicates that HITI is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 3.06, HITI belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
HITI has a debt to FCF ratio of 4.08. This is a neutral value as HITI would need 4.08 years to pay back of all of its debts.
HITI has a better Debt to FCF ratio (4.08) than 84.38% of its industry peers.
A Debt/Equity ratio of 0.43 indicates that HITI is not too dependend on debt financing.
HITI's Debt to Equity ratio of 0.43 is on the low side compared to the rest of the industry. HITI is outperformed by 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 4.08 | ||
| Altman-Z | 3.06 |
ROIC/WACC0.6
WACC7.74%
2.3 Liquidity
HITI has a Current Ratio of 1.85. This is a normal value and indicates that HITI is financially healthy and should not expect problems in meeting its short term obligations.
HITI has a Current ratio (1.85) which is comparable to the rest of the industry.
A Quick Ratio of 1.29 indicates that HITI should not have too much problems paying its short term obligations.
HITI has a Quick ratio of 1.29. This is comparable to the rest of the industry: HITI outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
HITI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -328.07%.
HITI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.18%.
HITI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 75.59% yearly.
EPS 1Y (TTM)-328.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)11.18%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%13.67%
3.2 Future
Based on estimates for the next years, HITI will show a very strong growth in Earnings Per Share. The EPS will grow by 74.44% on average per year.
The Revenue is expected to grow by 15.68% on average over the next years. This is quite good.
EPS Next Y3.81%
EPS Next 2Y103.67%
EPS Next 3Y96.71%
EPS Next 5Y74.44%
Revenue Next Year13.63%
Revenue Next 2Y21.39%
Revenue Next 3Y17.79%
Revenue Next 5Y15.68%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HITI. In the last year negative earnings were reported.
HITI is valuated quite expensively with a Price/Forward Earnings ratio of 27.26.
71.88% of the companies in the same industry are more expensive than HITI, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of HITI to the average of the S&P500 Index (34.08), we can say HITI is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.26 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HITI is valued a bit cheaper than the industry average as 71.88% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, HITI is valued a bit cheaper than the industry average as 65.63% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.34 | ||
| EV/EBITDA | 9.33 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
HITI's earnings are expected to grow with 96.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y103.67%
EPS Next 3Y96.71%
5. Dividend
5.1 Amount
No dividends for HITI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:HITI (11/20/2025, 7:00:00 PM)
3.69
-0.11 (-2.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners6.97%
Inst Owner ChangeN/A
Ins Owners8.32%
Ins Owner ChangeN/A
Market Cap321.88M
Revenue(TTM)568.25M
Net Income(TTM)-9.80M
Analysts80
Price Target7.4 (100.54%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)194.66%
Min EPS beat(2)-8%
Max EPS beat(2)397.33%
EPS beat(4)1
Avg EPS beat(4)15.55%
Min EPS beat(4)-315.76%
Max EPS beat(4)397.33%
EPS beat(8)5
Avg EPS beat(8)75.15%
EPS beat(12)9
Avg EPS beat(12)61.94%
EPS beat(16)12
Avg EPS beat(16)45.88%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)3
Avg Revenue beat(4)0.59%
Min Revenue beat(4)-1.49%
Max Revenue beat(4)1.6%
Revenue beat(8)5
Avg Revenue beat(8)0.02%
Revenue beat(12)9
Avg Revenue beat(12)1.49%
Revenue beat(16)13
Avg Revenue beat(16)7.4%
PT rev (1m)0.87%
PT rev (3m)-3.33%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)14.29%
EPS NY rev (3m)-9.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.53%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)2.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.26 | ||
| P/S | 0.57 | ||
| P/FCF | 16.34 | ||
| P/OCF | 11.01 | ||
| P/B | 2.28 | ||
| P/tB | 6.2 | ||
| EV/EBITDA | 9.33 |
EPS(TTM)-0.13
EYN/A
EPS(NY)0.14
Fwd EY3.67%
FCF(TTM)0.23
FCFY6.12%
OCF(TTM)0.34
OCFY9.08%
SpS6.51
BVpS1.62
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.76% | ||
| ROE | -6.93% | ||
| ROCE | 6.4% | ||
| ROIC | 4.61% | ||
| ROICexc | 6.71% | ||
| ROICexgc | 18.48% | ||
| OM | 2.3% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% | ||
| FCFM | 3.47% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
F-Score5
Asset Turnover2.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 4.08 | ||
| Debt/EBITDA | 1.67 | ||
| Cap/Depr | 41.17% | ||
| Cap/Sales | 1.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 80.65% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | 3.06 |
F-Score5
WACC7.74%
ROIC/WACC0.6
Cap/Depr(3y)28.99%
Cap/Depr(5y)34.63%
Cap/Sales(3y)1.88%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-328.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y3.81%
EPS Next 2Y103.67%
EPS Next 3Y96.71%
EPS Next 5Y74.44%
Revenue 1Y (TTM)11.18%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%13.67%
Revenue Next Year13.63%
Revenue Next 2Y21.39%
Revenue Next 3Y17.79%
Revenue Next 5Y15.68%
EBIT growth 1Y2.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year418.19%
EBIT Next 3Y133.23%
EBIT Next 5Y81.34%
FCF growth 1Y38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.53%
OCF growth 3YN/A
OCF growth 5YN/A
HIGH TIDE INC / HITI.CA FAQ
What is the fundamental rating for HITI stock?
ChartMill assigns a fundamental rating of 4 / 10 to HITI.CA.
What is the valuation status of HIGH TIDE INC (HITI.CA) stock?
ChartMill assigns a valuation rating of 4 / 10 to HIGH TIDE INC (HITI.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for HIGH TIDE INC?
HIGH TIDE INC (HITI.CA) has a profitability rating of 3 / 10.
What is the financial health of HIGH TIDE INC (HITI.CA) stock?
The financial health rating of HIGH TIDE INC (HITI.CA) is 5 / 10.
Can you provide the expected EPS growth for HITI stock?
The Earnings per Share (EPS) of HIGH TIDE INC (HITI.CA) is expected to grow by 3.81% in the next year.